Canaccord raised the firm’s price target on Repligen (RGEN) to $170 from $165 and keeps a Buy rating on the shares. The firm said they reported solid Q4 results and are encouraged by the company’s commentary regarding orders, leading to a solid initial outlook for 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen Corporation Announces 2024 Financial Results
- Hold Rating for Repligen Amid Mixed Performance and Modest Growth Projections
- Repligen price target raised to $165 from $160 at Jefferies
- Repligen’s Strong Market Position and Growth Potential: A Buy Recommendation
- Repligen reports Q4 adjusted EPS 44c, consensus 41c